Prasad Suyash's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed Jul 1, 2022
- Accession no.
- 0001209191-22-040356
- Filed
- Jul 1, 2022
- Trade date
- Jun 29-Jul 1, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $183.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Prasad SuyashCIK 0001679129 | Officer (CMO and Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2022 | Common Stock | SSaleDisposed | −12,324 | $3.81 | −$46,954.44 | 581,265 | Direct | |
| Jun 30, 2022 | Common Stock | SSaleDisposed | −13,892 | $3.72 | −$51,678.24 | 567,373 | Direct | |
| Jul 1, 2022 | Common Stock | SSaleDisposed | −23,923 | $3.53 | −$84,448.19 | 543,450 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.